Safety of 9-valent human papillomavirus vaccine administration among pregnant women: Adverse event reports in the Vaccine Adverse Event Reporting System (VAERS), 2014-2017
- PMID: 30660400
- PMCID: PMC6505695
- DOI: 10.1016/j.vaccine.2018.11.077
Safety of 9-valent human papillomavirus vaccine administration among pregnant women: Adverse event reports in the Vaccine Adverse Event Reporting System (VAERS), 2014-2017
Abstract
Introduction: 9-valent human papillomavirus vaccine (9vHPV) was approved by the Food and Drug Administration (FDA) in December 2014. 9vHPV is not recommended during pregnancy, but some women of childbearing age may be inadvertently exposed. This study aims to evaluate reports submitted to the Vaccine Adverse Event Reporting System (VAERS) of pregnant women exposed to 9vHPV.
Methods: We searched the VAERS database, a national post-licensure vaccine safety surveillance system, for reports of pregnant women vaccinated with 9vHPV in the United States between December 10, 2014 and December 31, 2017. Disproportionate reporting of adverse events (AEs) was assessed using proportional reporting ratios (PRRs).
Results: A total of 82 pregnancy reports were identified. Sixty reports (73.2%) did not describe an AE and were submitted only to report the vaccine exposure during pregnancy. The most frequently reported pregnancy-specific AE was spontaneous abortion (n = 3; 3.7%), followed by vaginal bleeding (n = 2; 2.4%). Among non-pregnancy-specific AEs, injection site reaction (n = 3; 3.7%) was most common. No disproportionate reporting of any AE was found.
Discussion: No unexpected AEs were observed among these pregnancy reports.
Keywords: Adverse event; Epidemiology; Human papillomavirus vaccine; Surveillance; Vaccine safety.
Copyright © 2018 Elsevier Ltd. All rights reserved.
Figures
Similar articles
-
Post-licensure safety surveillance of 23-valent pneumococcal polysaccharide vaccine in the Vaccine Adverse Event Reporting System (VAERS), 1990-2013.Vaccine. 2016 May 27;34(25):2841-6. doi: 10.1016/j.vaccine.2016.04.021. Epub 2016 Apr 15. Vaccine. 2016. PMID: 27087150 Free PMC article.
-
Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015.Vaccine. 2018 Mar 20;36(13):1781-1788. doi: 10.1016/j.vaccine.2018.02.034. Epub 2018 Feb 21. Vaccine. 2018. PMID: 29477308
-
Assessing the safety of hepatitis B vaccination during pregnancy in the Vaccine Adverse Event Reporting System (VAERS), 1990-2016.Vaccine. 2018 Jan 2;36(1):50-54. doi: 10.1016/j.vaccine.2017.11.039. Epub 2017 Nov 27. Vaccine. 2018. PMID: 29174107 Free PMC article.
-
Monitoring the safety of high-dose, trivalent inactivated influenza vaccine in the vaccine adverse event reporting system (VAERS), 2011 - 2019.Vaccine. 2020 Aug 18;38(37):5923-5926. doi: 10.1016/j.vaccine.2020.07.007. Epub 2020 Jul 21. Vaccine. 2020. PMID: 32709434 Review.
-
Adverse events following quadrivalent meningococcal diphtheria toxoid conjugate vaccine (Menactra®) reported to the Vaccine Adverse Event Reporting System (VAERS), 2005-2016.Vaccine. 2020 Sep 11;38(40):6291-6298. doi: 10.1016/j.vaccine.2020.07.039. Epub 2020 Jul 31. Vaccine. 2020. PMID: 32747215 Free PMC article. Review.
Cited by
-
Vaccine Safety Datalink infrastructure enhancements for evaluating the safety of maternal vaccination.Ther Adv Drug Saf. 2021 Jun 14;12:20420986211021233. doi: 10.1177/20420986211021233. eCollection 2021. Ther Adv Drug Saf. 2021. PMID: 34178302 Free PMC article.
-
Association of Inadvertent 9-Valent Human Papillomavirus Vaccine in Pregnancy With Spontaneous Abortion and Adverse Birth Outcomes.JAMA Netw Open. 2021 Apr 1;4(4):e214340. doi: 10.1001/jamanetworkopen.2021.4340. JAMA Netw Open. 2021. PMID: 33818618 Free PMC article.
References
-
- Gruber MF. December 10, 2014 Approval letter—GARDASIL 9. Silver Spring, MD: U.S. Department of Health and Human Services, Food and Drug Administration; 2014.
-
- Centers for Disease Control and Prevention. HPV Vaccine Information for Clinicians. U.S. Department of Health and Human Services; https://www.cdc.gov/hpv/hcp/need-to-know.pdf. Published December 20, 2016. Accessed January 2018.
-
- Meites E, Kempe A, Markowitz LE. Use of a 2-Dose Schedule for Human Papillomavirus Vaccination - Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR Morbidity and mortality weekly report. 2016;65(49):1405–8. - PubMed
-
- Merck Sharp & Dohme Corp. Highlights of Prescribing Information Gardasil®9 (Human Papillomavirus 9-valent Vaccine, Recombinant). Merck & Co., Inc; https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedPr.... Published 2014. Updated February 2018. Accessed April 2018.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical